| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/20/2006 | CA2603295A1 Use of ghrelin for the treatment of hyperthyroidism |
| 10/19/2006 | WO2006110924A2 Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration |
| 10/19/2006 | WO2006110887A2 Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling |
| 10/19/2006 | WO2006110743A1 Use of natriuretic peptide for treating heart failure |
| 10/19/2006 | WO2006110623A2 Targeted cholera toxin for treatment of persistent or chonic pain |
| 10/19/2006 | WO2006110608A2 Compositions and method for increasing the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors |
| 10/19/2006 | WO2006110591A2 POP2 NFkB-INHIBITING POLYPEPTIDES, NUCLEIC ACIDS AND METHODS OF USE |
| 10/19/2006 | WO2006110577A2 Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| 10/19/2006 | WO2006109855A1 Peptide having food intake stimulating effect and method for screening for the peptide |
| 10/19/2006 | WO2006109698A1 Composition comprising genetically engineered erythropoietin |
| 10/19/2006 | WO2006109696A1 Composition comprising genetically engineered follicle-stimulating hormone |
| 10/19/2006 | WO2006109695A1 Composition comprising genetically engineered haptoglobin |
| 10/19/2006 | WO2006109675A1 Antitumor agent and novel dnase |
| 10/19/2006 | WO2006109635A1 Intestinal absorptive anti-tumor agent |
| 10/19/2006 | WO2006109367A1 Cell release method, cell release solution, cell culture method, cell culture medium, cell solution, cell solution preparation, cell colonization method and cell colonization solution |
| 10/19/2006 | WO2006109312A2 Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
| 10/19/2006 | WO2006109303A2 Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them |
| 10/19/2006 | WO2006109301A2 Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
| 10/19/2006 | WO2006109286A1 Filamentous hemagglutinin for the prevention of the development of neutralising antibodies to a biologic agent |
| 10/19/2006 | WO2006109285A1 Methods and compounds for the treatment of autoimmune diseases and chronic inflammatory conditions |
| 10/19/2006 | WO2006109284A1 Use of filamentous hemagglutinin for the treatment of cognitive dysfunction and neurodegenerative disorders |
| 10/19/2006 | WO2006109192A2 Antifungal bifunctional molecules, methods of construction and methods of treating fungal infection therewith |
| 10/19/2006 | WO2006109092A1 Conjugate comprising p21 protein for the treatment of cancer |
| 10/19/2006 | WO2006109044A2 Selective modulation of tumour necrosis factor receptors in therapy |
| 10/19/2006 | WO2006108963A1 Use of a peptide in the form of a slimming active principle |
| 10/19/2006 | WO2006108844A1 Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab) |
| 10/19/2006 | WO2006108718A1 Micro rna |
| 10/19/2006 | WO2006108686A2 Bnp agonists |
| 10/19/2006 | WO2006108586A2 Polymyxin b analogs for lps detoxification |
| 10/19/2006 | WO2006108270A1 Inhibitors of protein kinases and uses thereof |
| 10/19/2006 | WO2006108239A1 Ocular drug delivery |
| 10/19/2006 | WO2006108218A1 Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
| 10/19/2006 | WO2006084139A3 An implantable interferon-containing device |
| 10/19/2006 | WO2006079722A3 Compositions for freeze-drying proteins |
| 10/19/2006 | WO2006079121A3 Methods of treating disease with glycosylated interferon |
| 10/19/2006 | WO2006078648A3 Rhinovirus vaccines |
| 10/19/2006 | WO2006078277A3 Dalbavancin compositions for treatment of bacterial infections |
| 10/19/2006 | WO2006075138A3 Il-10 related peptides for wound healing |
| 10/19/2006 | WO2006074419A3 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| 10/19/2006 | WO2006048449A3 Mc4r selective peptides and their use in the treatment of obesity |
| 10/19/2006 | WO2006044335A3 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer |
| 10/19/2006 | WO2006032042A3 Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity |
| 10/19/2006 | WO2006023791A3 Methods and compositions for treating allergic inflammation |
| 10/19/2006 | WO2006007560A3 Targeted protein replacement for the treatment of lysosomal storage disorders |
| 10/19/2006 | WO2005117943A3 Biomarkers for monitoring inhibition of impdh pathway |
| 10/19/2006 | WO2005097179A3 Stabilised tat antigen and the use thereof for anti-hiv vaccination |
| 10/19/2006 | WO2005068632A8 EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
| 10/19/2006 | WO2005034860A3 Thiol reactive agents as a therapeutic modality |
| 10/19/2006 | WO2005007878A3 Method of modulating apoptosis and compositions thereof |
| 10/19/2006 | WO2004106491A8 Angiogenin-based hiv-1 therapies |
| 10/19/2006 | WO2004084810A3 Novel imidazoline receptor homologs |
| 10/19/2006 | WO2003027637A3 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 10/19/2006 | US20060235204 BMP-2 variants with improved properties |
| 10/19/2006 | US20060235203 MN gene and protein |
| 10/19/2006 | US20060235200 Mutagenesis of aspergillus fungi and identification of genes essential for growth |
| 10/19/2006 | US20060235052 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses |
| 10/19/2006 | US20060234994 Method and device for concentrating and stabilizing conjugated estrogens from mare urine |
| 10/19/2006 | US20060234971 Calpains as targets for inhibition of prion propagation |
| 10/19/2006 | US20060234968 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 10/19/2006 | US20060234966 Method for expressing inducible rna [in cells, nucleic acid molecules therefor and cells transformed by said molecules |
| 10/19/2006 | US20060234947 A synthetic dipeptide as set forth in SEQ ID NO: 145 - tryptophan-2-aminoisobutyric acid (D-Trp-Aib); diagnosing and treating Alzheimer's disease, non-insulin dependent diabtes; antdiabetic agents, prion-related encephalopathies such as bovine spongiform encephalo pathy |
| 10/19/2006 | US20060234946 Use of telmisartan for the prevention and treatment of vascular headache |
| 10/19/2006 | US20060234945 Ophthalmic therapeutic composition |
| 10/19/2006 | US20060234944 Beta-secretase inhibitors and methods of use |
| 10/19/2006 | US20060234943 Biological active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (ivtntt) |
| 10/19/2006 | US20060234942 Use of at least one $g(a)62 casein peptide with angiotensin i converting enzyme inhibiting activity for preparing medicines, food products and food complements |
| 10/19/2006 | US20060234941 Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| 10/19/2006 | US20060234940 Secondary binding site of dipeptidyl peptidase IV (DP IV) |
| 10/19/2006 | US20060234939 Calcium channel modulator; delayed or sustained release |
| 10/19/2006 | US20060234938 Amino acid sequences which target pre-B-cell transformation related gene (PBX) expression for use in treatment of cell proliferative disorders; antiproliferative agents |
| 10/19/2006 | US20060234937 Modulation of angiogenesis |
| 10/19/2006 | US20060234936 Method for screening substances capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells |
| 10/19/2006 | US20060234935 Mutants of the factor VII epidermal growth factor domain |
| 10/19/2006 | US20060234934 Composition and Method for Selective Cytostasis |
| 10/19/2006 | US20060234933 Pituitary adenylate cyclase activating peptide; solid phase synthesis; diabetes, insulin resistance, metabolic acidosis and obesity |
| 10/19/2006 | US20060234932 Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes |
| 10/19/2006 | US20060234931 Treatment of diseases with kinase inhibitors |
| 10/19/2006 | US20060234930 Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 10/19/2006 | US20060234929 Rasgap derived peptide for selectively killing cancer cells |
| 10/19/2006 | US20060234928 Cell death-inducing fused gene acting specifically on cancer and gene product thereof |
| 10/19/2006 | US20060234927 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 10/19/2006 | US20060234926 Nucleic acid ligands and uses therefor |
| 10/19/2006 | US20060234925 Embryo implantation inhibitor |
| 10/19/2006 | US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis |
| 10/19/2006 | US20060234923 solid phase synthesis; solution phase synthesis; hairpin motifs; chemokine receptor 4 antagonists |
| 10/19/2006 | US20060234922 Remedy for corneal failure |
| 10/19/2006 | US20060234921 Treatment of osteoarthritis |
| 10/19/2006 | US20060234920 New antitumoral compounds |
| 10/19/2006 | US20060234919 Use |
| 10/19/2006 | US20060234918 Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| 10/19/2006 | US20060234917 glycoprotein comprising the extracellular domain of a non-naturally occurring BAFF-R; BAFF (B-cell-activating factor of the TNF family); immunologic, autoimmune diseases, cancers, virus-associated diseases, renal, hypertensive diseases, conditions requiring immunosuppression, inflammation |
| 10/19/2006 | US20060234916 Cardioprotective agent |
| 10/19/2006 | US20060234915 Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers |
| 10/19/2006 | US20060234914 Fragments of proinsulin c-peptide |
| 10/19/2006 | US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia |
| 10/19/2006 | US20060234912 Methods for modulating neuronal responses |
| 10/19/2006 | US20060234911 Method of reversing epithelial mesenchymal transition |
| 10/19/2006 | US20060234910 Methods for the treatment of insulin resistance and disease states characterized by insulin resistance |
| 10/19/2006 | US20060234909 Compositions and methods for increasing drug efficiency |
| 10/19/2006 | US20060234908 Methods for improving the structure and function of arterioles |